Table 3 LTP treatment prescriptions, overall and by country
n (%) | Overall (N = 225) | US (n = 56) | Canada (n = 51) | Germany (n = 45) | Australia (n = 35) | UK (n = 24) | Italy (n = 14) |
|---|---|---|---|---|---|---|---|
Patients with any LTP usea | 121 (53.8) | 34 (60.7) | 33 (64.7) | 13 (28.9) | 19 (54.3) | 21 (87.5) | 1 (7.1) |
Plasma-derived C1-INH | |||||||
 Berinert® | 31 (25.6) | 2 (5.9) | 17 (51.5) | 4 (30.8) | 7 (36.8) | 1 (4.8) | 0 |
  Intravenous | 25 (20.7) | 2 (5.9) | 14 (42.4) | 1 (7.7) | 7 (36.8) | 1 (4.8) | 0 |
  Subcutaneousb | 8 (6.6) | 0 | 4 (12.1) | 4 (30.8) | 0 | 0 | 0 |
 Cinryze® | 36 (29.8) | 21 (61.8) | 6 (18.2) | 7 (53.8) | 0 | 2 (9.5) | 0 |
 Haegarda® | 9 (7.4) | 9 (26.5) | 0 | 0 | 0 | 0 | 0 |
Androgen therapy | |||||||
 Danazol | 65 (53.7) | 15 (44.1) | 19 (57.6) | 2 (15.4) | 11 (57.9) | 18 (85.7) | 0 |
 Stanozolol | 7 (5.8) | 3 (8.8) | 1 (3.0) | 0 | 3 (15.8) | 0 | 0 |
 Oxandrolone | 3 (2.5) | 0 | 0 | 0 | 1 (5.3) | 2 (9.5) | 0 |
Tranexamic acid | 15 (12.4) | 0 | 5 (15.2) | 0 | 7 (36.8) | 2 (9.5) | 1 (100.0) |
Ruconest® | 1 (0.8) | 1 (2.9) | 0 | 0 | 0 | 0 | 0 |
Lanadelumab | 11 (9.1) | 7 (20.6) | 0 | 4 (30.8) | 0 | 0 | 0 |